Open‐label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease
Identifieur interne : 001248 ( Main/Exploration ); précédent : 001247; suivant : 001249Open‐label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease
Auteurs : Theresa A. Zesiewicz [États-Unis] ; Kelly L. Sullivan [États-Unis] ; Robert A. Hauser [États-Unis] ; Juan Sanchez-Ramos [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2006-11.
English descriptors
- KwdEn :
Abstract
The objective of this study is to evaluate the tolerability and preliminary efficacy of levetiracetam (LEV) in reducing chorea in Huntington's disease (HD) patients in a prospective open‐label pilot study. Nine HD patients with chorea were treated with LEV in doses up to 3,000 mg/day for up to 48 days. The primary endpoint measure was the Unified Huntington's Disease Rating Scale (UHDRS) chorea subscore. The mean dose (±SD) of LEV at endpoint was 2,583.3 ± 1,020.6 mg/day. Mean UHDRS chorea score decreased from 12.6 ± 3.0 at baseline to 6.7 ± 4.3 at endpoint (P = 0.01). There was no significant change in UHDRS total motor scores (38.8 ± 11.4 at baseline and 33.6 ± 26.7 at endpoint; P = 0.24). Somnolence contributed to a 33% drop‐out rate, and 3 patients developed Parkinsonism. Results of this open label study suggest that LEV may be efficacious in reducing chorea in HD patients. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.21061
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Open‐label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease</title>
<author><name sortKey="Zesiewicz, Theresa A" sort="Zesiewicz, Theresa A" uniqKey="Zesiewicz T" first="Theresa A." last="Zesiewicz">Theresa A. Zesiewicz</name>
</author>
<author><name sortKey="Sullivan, Kelly L" sort="Sullivan, Kelly L" uniqKey="Sullivan K" first="Kelly L." last="Sullivan">Kelly L. Sullivan</name>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
</author>
<author><name sortKey="Sanchez Amos, Juan" sort="Sanchez Amos, Juan" uniqKey="Sanchez Amos J" first="Juan" last="Sanchez-Ramos">Juan Sanchez-Ramos</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:298284E6EA71525F8E1A0FAFDA76BECAF0FCEE4B</idno>
<date when="2006" year="2006">2006</date>
<idno type="doi">10.1002/mds.21061</idno>
<idno type="url">https://api.istex.fr/document/298284E6EA71525F8E1A0FAFDA76BECAF0FCEE4B/fulltext/pdf</idno>
<idno type="wicri:Area/Main/Corpus">002B97</idno>
<idno type="wicri:Area/Main/Curation">002828</idno>
<idno type="wicri:Area/Main/Exploration">001248</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Open‐label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease</title>
<author><name sortKey="Zesiewicz, Theresa A" sort="Zesiewicz, Theresa A" uniqKey="Zesiewicz T" first="Theresa A." last="Zesiewicz">Theresa A. Zesiewicz</name>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Sullivan, Kelly L" sort="Sullivan, Kelly L" uniqKey="Sullivan K" first="Kelly L." last="Sullivan">Kelly L. Sullivan</name>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Sanchez Amos, Juan" sort="Sanchez Amos, Juan" uniqKey="Sanchez Amos J" first="Juan" last="Sanchez-Ramos">Juan Sanchez-Ramos</name>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinson's Disease and Movement Disorders Center and Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2006-11">2006-11</date>
<biblScope unit="volume">21</biblScope>
<biblScope unit="issue">11</biblScope>
<biblScope unit="page" from="1998">1998</biblScope>
<biblScope unit="page" to="2001">2001</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">298284E6EA71525F8E1A0FAFDA76BECAF0FCEE4B</idno>
<idno type="DOI">10.1002/mds.21061</idno>
<idno type="ArticleID">MDS21061</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Huntington's disease</term>
<term>Keppra</term>
<term>chorea</term>
<term>levetiracetam</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The objective of this study is to evaluate the tolerability and preliminary efficacy of levetiracetam (LEV) in reducing chorea in Huntington's disease (HD) patients in a prospective open‐label pilot study. Nine HD patients with chorea were treated with LEV in doses up to 3,000 mg/day for up to 48 days. The primary endpoint measure was the Unified Huntington's Disease Rating Scale (UHDRS) chorea subscore. The mean dose (±SD) of LEV at endpoint was 2,583.3 ± 1,020.6 mg/day. Mean UHDRS chorea score decreased from 12.6 ± 3.0 at baseline to 6.7 ± 4.3 at endpoint (P = 0.01). There was no significant change in UHDRS total motor scores (38.8 ± 11.4 at baseline and 33.6 ± 26.7 at endpoint; P = 0.24). Somnolence contributed to a 33% drop‐out rate, and 3 patients developed Parkinsonism. Results of this open label study suggest that LEV may be efficacious in reducing chorea in HD patients. © 2006 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Floride</li>
</region>
<settlement><li>Tampa</li>
</settlement>
<orgName><li>Université de Floride du Sud</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="Floride"><name sortKey="Zesiewicz, Theresa A" sort="Zesiewicz, Theresa A" uniqKey="Zesiewicz T" first="Theresa A." last="Zesiewicz">Theresa A. Zesiewicz</name>
</region>
<name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<name sortKey="Sanchez Amos, Juan" sort="Sanchez Amos, Juan" uniqKey="Sanchez Amos J" first="Juan" last="Sanchez-Ramos">Juan Sanchez-Ramos</name>
<name sortKey="Sanchez Amos, Juan" sort="Sanchez Amos, Juan" uniqKey="Sanchez Amos J" first="Juan" last="Sanchez-Ramos">Juan Sanchez-Ramos</name>
<name sortKey="Sanchez Amos, Juan" sort="Sanchez Amos, Juan" uniqKey="Sanchez Amos J" first="Juan" last="Sanchez-Ramos">Juan Sanchez-Ramos</name>
<name sortKey="Sullivan, Kelly L" sort="Sullivan, Kelly L" uniqKey="Sullivan K" first="Kelly L." last="Sullivan">Kelly L. Sullivan</name>
<name sortKey="Sullivan, Kelly L" sort="Sullivan, Kelly L" uniqKey="Sullivan K" first="Kelly L." last="Sullivan">Kelly L. Sullivan</name>
<name sortKey="Zesiewicz, Theresa A" sort="Zesiewicz, Theresa A" uniqKey="Zesiewicz T" first="Theresa A." last="Zesiewicz">Theresa A. Zesiewicz</name>
<name sortKey="Zesiewicz, Theresa A" sort="Zesiewicz, Theresa A" uniqKey="Zesiewicz T" first="Theresa A." last="Zesiewicz">Theresa A. Zesiewicz</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001248 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001248 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonV1 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:298284E6EA71525F8E1A0FAFDA76BECAF0FCEE4B |texte= Open‐label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease }}
This area was generated with Dilib version V0.6.23. |